Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience
Annals of Hematology · 04.11.2026
DOI: 10.1007/s00277-026-07346-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 04.11.2026. Verfasst von Gaia Ciolli und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AIRC 5x1000 call "Metastatic disease: the key unmet need in oncology" to MYNERVA project.
Abstract (Originalsprache)
Limited benefit of clofarabine and cytarabine in patients with acute myeloid leukemia after venetoclax failure. Acute myeloid leukemia (AML) is an aggressive blood cancer. Many patients are treated with venetoclax, but in some cases the disease stops responding to this treatment. When this happens, treatment options are limited and outcomes are often poor. This study looked at whether a combination of two chemotherapy drugs, clofarabine and cytarabine, could help patients whose AML had come back or did not respond after venetoclax treatment. Researchers reviewed past cases of patients treated at a single hospital in Florence (Italy). They compared two groups: one treated with clofarabine and cytarabine after venetoclax failure, and another historical group treated with the same chemotherapy before venetoclax was widely used. The results showed that the chemotherapy combination had very limited benefit in patients whose disease had already failed venetoclax. Only 1 out of 9 patients showed some response, and overall survival was short. In contrast, patients treated before the use of venetoclax had better outcomes, with more patients responding to treatment and slightly longer survival. Early deaths were also more frequent in the group previously treated with venetoclax. However, patients in the venetoclax group had received more previous treatments and had more often relapsed after a stem cell transplant, so the differences between the two groups cannot be attributed to venetoclax alone. In summary, this study suggests that clofarabine and cytarabine may not be effective for patients whose AML no longer responds to venetoclax, particularly after several previous lines of treatment. These findings highlight the need for new and better treatment options, ideally tested in clinical trials, for this difficult-to-treat group of patients. Resistance to venetoclax (VEN)-based therapies is a therapeutic challenge in acute myeloid leukemia (AML). To evaluate the efficacy of clofarabine in combination with intermediate-dose cytarabine in patients with VEN-resistant AML. We retrospectively analyzed two single-center cohorts of adult patients with relapsed/refractory (R/R) AML treated with clofarabine 22.5 mg/m²/day plus cytarabine 1 g/m²/day on days 1–5: a VEN-failure cohort ( n = 9) and a historical pre-VEN cohort ( n = 33), used as a contextual reference. In the VEN-failure cohort 11% of patients achieved partial response (PR), 89% were refractory (ORR 11%). The median OS was 2.0 months. Early mortality occurred in 33% of patients. In the pre-VEN cohort 33% of patients achieved complete remission, 6% PR (ORR 39%). The median OS was 4.0 months. Early mortality was recorded in 3% of patients. In this limited, retrospective single-center experience, clofarabine plus intermediate-dose cytarabine showed minimal clinical activity and an unfavorable early toxicity profile in heavily pretreated VEN-exposed R/R AML patients. The comparison with the pre-VEN cohort is contextual only and does not allow the inferior outcomes to be attributed to prior VEN exposure itself. Nevertheless, these real-world data add to the limited evidence available after VEN failure and may help to inform salvage treatment decisions in this setting. Enrollment in clinical trials should be prioritized for patients failing VEN-based therapy.
Förderung
- AIRC 5x1000 call "Metastatic disease: the key unmet need in oncology" to MYNERVA project
Zitieren
APA
Ciolli, G., Piccini, M., Scappini, B., Crupi, F., Pasquini, A., Caroprese, J., Cannetti, G., Lucarelli, C., Machetti, A., Guglielmelli, P., Vannucchi, A. M., & Mannelli, F. (2026). Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience. Annals of Hematology. https://doi.org/10.1007/s00277-026-07346-w
Vancouver
Ciolli G, Piccini M, Scappini B, Crupi F, Pasquini A, Caroprese J, et al. Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience. Annals of Hematology. 2026. doi:10.1007/s00277-026-07346-w
BibTeX
@article{Ciolli2026,
author = {Ciolli, Gaia and Piccini, Matteo and Scappini, Barbara and Crupi, Francesca and Pasquini, Andrea and Caroprese, Jessica and Cannetti, Giorgio and Lucarelli, Chiara and Machetti, Asia and Guglielmelli, Paola and Vannucchi, Alessandro M. and Mannelli, Francesco},
title = {Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07346-w}
}
EUVIMED